We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-5.38%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$530M
AUM Growth
+$88.9M
Cap. Flow
+$121M
Cap. Flow %
22.77%
Top 10 Hldgs %
58.16%
Holding
331
New
70
Increased
91
Reduced
51
Closed
65

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$32.3M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$24M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.5M
4
ROIV icon
Roivant Sciences
ROIV
+$14.9M
5
RPRX icon
Royalty Pharma
RPRX
+$12.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.3M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$3.85M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$3.78M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.42%
2 Financials 1.75%
3 Industrials 0.22%
4 Utilities 0.17%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLYB icon
226
Rallybio
RLYB
$85.9M
$15K ﹤0.01%
1,400
-843
-38% -$11.4K
GLSTR
227
DELISTED
Global Star Acquisition, Inc. Right
GLSTR
$14.8K ﹤0.01%
118,400
– –
OVID icon
228
Ovid Therapeutics
OVID
$495M
$14.8K ﹤0.01%
19,190
+2,744
+17% +$7.64K
ARQT icon
229
Arcutis Biotherapeutics
ARQT
$3.31B
$14.5K ﹤0.01%
1,555
-2,699
-63% -$24.4K
CLDX icon
230
Celldex Therapeutics
CLDX
$3.26B
$11.2K ﹤0.01%
+303
New +$11.4K
IDYA icon
231
IDEAYA Biosciences
IDYA
$3.49B
$10.5K ﹤0.01%
+300
New +$11.9K
ZVRA icon
232
Zevra Therapeutics
ZVRA
$702M
$9.8K ﹤0.01%
+2,000
New +$9.48K
OKLO
233
Oklo
OKLO
$7.34B
$8.47K ﹤0.01%
+1,000
New +$11.3K
AZN icon
234
AstraZeneca
AZN
$250B
$7.8K ﹤0.01%
50
-50
-50% -$7.52K
OAKUR
235
DELISTED
Oak Woods Acquisition Corp Right
OAKUR
$7.5K ﹤0.01%
30,000
– –
ADXN
236
Addex Therapeutics
ADXN
$7.34M
$7.4K ﹤0.01%
900
+510
+131% +$6.28K
ERAS icon
237
Erasca
ERAS
$6.34B
$7.32K ﹤0.01%
+3,100
New +$6.69K
EQ icon
238
CALL
Equillium
EQ
$134M
$6.1K ﹤0.01%
8,800
-1,200
-12% -$1.71K
BLUE
239
DELISTED
bluebird bio
BLUE
$5.91K ﹤0.01%
300
+50
+20% +$1K
ENGN icon
240
enGene Therapeutics
ENGN
$121M
$5.66K ﹤0.01%
+600
New +$7.7K
ACLX
241
DELISTED
Arcellx
ACLX
$5.52K ﹤0.01%
+100
New +$5.44K
CYTK icon
242
CALL
Cytokinetics
CYTK
$11B
$5.42K ﹤0.01%
100
-2,400
-96% -$145K
TYRA icon
243
Tyra Biosciences
TYRA
$1.61B
$4.8K ﹤0.01%
300
-28,000
-99% -$482K
MASI
244
DELISTED
Masimo
MASI
$4.79K ﹤0.01%
38
– –
ICHR icon
245
Ichor Holdings
ICHR
$2.45B
$4.16K ﹤0.01%
108
– –
JBIO
246
CALL
Jade Biosciences
JBIO
$1.35B
$4.15K ﹤0.01%
+71
New +$47.1K
ETON icon
247
Eton Pharmaceutcials
ETON
$1.26B
$3.95K ﹤0.01%
+1,200
New +$4.2K
TSVT
248
DELISTED
2seventy bio
TSVT
$3.85K ﹤0.01%
1,000
– –
APLS
249
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$3.84K ﹤0.01%
+100
New +$4.53K
OPTN
250
DELISTED
OptiNose
OPTN
$3.12K ﹤0.01%
+200
New +$3.35K
8 9
10
11 12

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, ADAR1 Capital Management held 331 positions worth $530M, up 20% from $441M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

ADAR1 Capital Management deployed $121M of net new capital in Q2 2024, opening 70 new positions and adding to 91 existing holdings. Its largest new stake was Perceptive Capital Solutions: 750,000 shares worth $7.54M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $28.1M trimmed.

  • ADAR1 Capital Management's largest Q2 2024 buy was Perceptive Capital Solutions: 750,000 shares worth $7.54M.
  • ADAR1 Capital Management added most to Cytokinetics in Q2 2024, an estimated $32.3M increase.
  • ADAR1 Capital Management's biggest Q2 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $28.1M.
  • ADAR1 Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $13.3M.
  • ADAR1 Capital Management's ten largest holdings make up 58% of its $530M portfolio in Q2 2024.
  • ADAR1 Capital Management opened 70 new positions and closed 65 in Q2 2024.
  • ADAR1 Capital Management's portfolio value rose 20% quarter-over-quarter to $530M.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.